1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
ASN 18 IS COVALENTLY BOUND THROUGH ND2 TO NAG 78 AT C1.
Fletcher, C.M.
Harrison, R.A.
Lachmann, P.J.
Neuhaus, D.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C6 H12 O5
164.156
alpha-L-fucopyranose
L-saccharide, alpha linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C8 H15 N O6
221.208
2-acetamido-2-deoxy-beta-D-glucopyranose
D-saccharide, beta linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C11 H12 N2 O2
204.225
y
TRYPTOPHAN
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
UK
Structure
STRUE6
2005
0969-2126
2
185
199
10.1016/S0969-2126(00)00020-4
7520819
Structure of a soluble, glycosylated form of the human complement regulatory protein CD59.
1994
US
Protein Sci.
PRCIEI
0795
0961-8368
2
2015
Sequence-Specific 1H-NMR Assignments and Folding Topology of Human Cd59
1993
US
Immunol.Res.
2031
0257-277X
12
258
Membrane Defence Against Complement Lysis: The Structure and Biological Properties of Cd59
1993
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
8970.106
CD59
1
man
polymer
570.542
2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
1
man
branched
no
no
LQCYNCPNPTADCKTAVNCSSDFDACLITKAGLQVYNKCWKFEHCNFNDVTTRLRENELTYYCCKKDLCNFNEQLEN
LQCYNCPNPTADCKTAVNCSSDFDACLITKAGLQVYNKCWKFEHCNFNDVTTRLRENELTYYCCKKDLCNFNEQLEN
A
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
human
sample
9606
Homo sapiens
atom_site
chem_comp
entity
pdbx_branch_scheme
pdbx_chem_comp_identifier
pdbx_database_status
pdbx_entity_branch
pdbx_entity_branch_descriptor
pdbx_entity_branch_link
pdbx_entity_branch_list
pdbx_entity_nonpoly
pdbx_nonpoly_scheme
pdbx_struct_assembly_gen
struct_asym
struct_conn
struct_site
struct_site_gen
repository
Initial release
Carbohydrate remediation
repository
Remediation
Version format compliance
Non-polymer description
Version format compliance
Atomic model
Data collection
Derived calculations
Other
Structure summary
1
0
1994-09-30
1
1
2008-03-24
1
2
2011-07-13
2
0
2020-07-29
_atom_site.auth_asym_id
_atom_site.auth_seq_id
_atom_site.label_asym_id
_atom_site.label_entity_id
_chem_comp.name
_chem_comp.type
_pdbx_database_status.process_site
_pdbx_struct_assembly_gen.asym_id_list
_struct_conn.pdbx_leaving_atom_flag
_struct_conn.pdbx_role
_struct_conn.ptnr1_auth_asym_id
_struct_conn.ptnr1_auth_seq_id
_struct_conn.ptnr2_auth_asym_id
_struct_conn.ptnr2_auth_seq_id
_struct_conn.ptnr2_label_asym_id
NAG
78
n
B
NAG
1
NAG
79
n
B
NAG
2
FUC
80
n
B
FUC
3
LFucpa
a-L-fucopyranose
a-L-Fucp
Fuc
DGlcpNAcb
N-acetyl-b-D-glucopyranosamine
b-D-GlcpNAc
GlcNAc
Y
BNL
1994-06-01
REL
oligosaccharide
DGlcpNAcb1-4[LFucpa1-6]DGlcpNAcb1-
2
GMML
1.0
Glycam Condensed Sequence
WURCS=2.0/2,3,2/[a2122h-1b_1-5_2*NCC/3=O][a1221m-1a_1-5]/1-1-2/a4-b1_a6-c1
2
PDB2Glycan
1.1.0
WURCS
[]{[(4+1)][b-D-GlcpNAc]{[(4+1)][b-D-GlcpNAc]{}[(6+1)][a-L-Fucp]{}}}
2
PDB-CARE
LINUCS
C1
O4
NAG
NAG
2
1
2
O1
HO4
sing
C1
O6
FUC
NAG
3
1
2
O1
HO6
sing
n
n
n
10
BRUNGER
refinement
X-PLOR
LEU
1
n
1
LEU
1
A
GLN
2
n
2
GLN
2
A
CYS
3
n
3
CYS
3
A
TYR
4
n
4
TYR
4
A
ASN
5
n
5
ASN
5
A
CYS
6
n
6
CYS
6
A
PRO
7
n
7
PRO
7
A
ASN
8
n
8
ASN
8
A
PRO
9
n
9
PRO
9
A
THR
10
n
10
THR
10
A
ALA
11
n
11
ALA
11
A
ASP
12
n
12
ASP
12
A
CYS
13
n
13
CYS
13
A
LYS
14
n
14
LYS
14
A
THR
15
n
15
THR
15
A
ALA
16
n
16
ALA
16
A
VAL
17
n
17
VAL
17
A
ASN
18
n
18
ASN
18
A
CYS
19
n
19
CYS
19
A
SER
20
n
20
SER
20
A
SER
21
n
21
SER
21
A
ASP
22
n
22
ASP
22
A
PHE
23
n
23
PHE
23
A
ASP
24
n
24
ASP
24
A
ALA
25
n
25
ALA
25
A
CYS
26
n
26
CYS
26
A
LEU
27
n
27
LEU
27
A
ILE
28
n
28
ILE
28
A
THR
29
n
29
THR
29
A
LYS
30
n
30
LYS
30
A
ALA
31
n
31
ALA
31
A
GLY
32
n
32
GLY
32
A
LEU
33
n
33
LEU
33
A
GLN
34
n
34
GLN
34
A
VAL
35
n
35
VAL
35
A
TYR
36
n
36
TYR
36
A
ASN
37
n
37
ASN
37
A
LYS
38
n
38
LYS
38
A
CYS
39
n
39
CYS
39
A
TRP
40
n
40
TRP
40
A
LYS
41
n
41
LYS
41
A
PHE
42
n
42
PHE
42
A
GLU
43
n
43
GLU
43
A
HIS
44
n
44
HIS
44
A
CYS
45
n
45
CYS
45
A
ASN
46
n
46
ASN
46
A
PHE
47
n
47
PHE
47
A
ASN
48
n
48
ASN
48
A
ASP
49
n
49
ASP
49
A
VAL
50
n
50
VAL
50
A
THR
51
n
51
THR
51
A
THR
52
n
52
THR
52
A
ARG
53
n
53
ARG
53
A
LEU
54
n
54
LEU
54
A
ARG
55
n
55
ARG
55
A
GLU
56
n
56
GLU
56
A
ASN
57
n
57
ASN
57
A
GLU
58
n
58
GLU
58
A
LEU
59
n
59
LEU
59
A
THR
60
n
60
THR
60
A
TYR
61
n
61
TYR
61
A
TYR
62
n
62
TYR
62
A
CYS
63
n
63
CYS
63
A
CYS
64
n
64
CYS
64
A
LYS
65
n
65
LYS
65
A
LYS
66
n
66
LYS
66
A
ASP
67
n
67
ASP
67
A
LEU
68
n
68
LEU
68
A
CYS
69
n
69
CYS
69
A
ASN
70
n
70
ASN
70
A
PHE
71
n
71
PHE
71
A
ASN
72
n
72
ASN
72
A
GLU
73
n
73
GLU
73
A
GLN
74
n
74
GLN
74
A
LEU
75
n
75
LEU
75
A
GLU
76
n
76
GLU
76
A
ASN
77
n
77
ASN
77
A
author_defined_assembly
1
monomeric
A
ASN
18
GLYCOSYLATION SITE
A
ASN
18
ASN
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
A
N
CYS
3
A
N
CYS
3
A
O
VAL
17
A
O
VAL
17
A
O
TRP
40
A
O
TRP
40
A
N
ALA
25
A
N
ALA
25
A
O
CYS
26
A
O
CYS
26
A
N
CYS
64
A
N
CYS
64
1
A
ARG
53
0.305
SIDE CHAIN
1
A
ARG
55
0.281
SIDE CHAIN
2
A
ARG
53
0.245
SIDE CHAIN
2
A
ARG
55
0.150
SIDE CHAIN
3
A
ARG
53
0.233
SIDE CHAIN
3
A
ARG
55
0.314
SIDE CHAIN
4
A
ARG
53
0.215
SIDE CHAIN
4
A
ARG
55
0.207
SIDE CHAIN
5
A
ARG
53
0.217
SIDE CHAIN
5
A
ARG
55
0.317
SIDE CHAIN
6
A
ARG
53
0.295
SIDE CHAIN
6
A
ARG
55
0.299
SIDE CHAIN
7
A
ARG
53
0.273
SIDE CHAIN
7
A
ARG
55
0.282
SIDE CHAIN
8
A
ARG
53
0.115
SIDE CHAIN
8
A
ARG
55
0.314
SIDE CHAIN
9
A
ARG
53
0.312
SIDE CHAIN
9
A
ARG
55
0.313
SIDE CHAIN
10
A
ARG
53
0.175
SIDE CHAIN
10
A
ARG
55
0.283
SIDE CHAIN
1
A
ASP
12
-171.84
42.84
1
A
LYS
14
-140.52
26.30
1
A
SER
20
-51.34
-177.33
1
A
ALA
31
-85.93
45.08
1
A
LEU
33
165.69
-45.89
1
A
PHE
47
-90.89
57.12
1
A
ASN
48
178.87
-32.75
1
A
GLU
56
-123.57
-157.66
1
A
ASN
57
-161.73
-75.40
1
A
GLU
58
-59.65
102.76
1
A
ASP
67
-45.44
97.95
1
A
LEU
68
79.43
70.19
1
A
PHE
71
-51.43
-179.82
1
A
GLU
73
-157.12
51.80
1
A
GLN
74
-160.42
26.15
1
A
LEU
75
-147.00
21.23
2
A
CYS
6
172.25
92.34
2
A
ASP
12
-166.01
34.40
2
A
VAL
17
177.67
137.20
2
A
CYS
19
-44.99
-75.01
2
A
SER
20
64.01
157.15
2
A
SER
21
79.78
52.11
2
A
ASP
22
63.06
81.57
2
A
ALA
31
-106.98
47.36
2
A
LEU
33
-171.79
-38.36
2
A
ASN
48
-178.09
-33.32
2
A
ASN
57
-140.61
-58.86
2
A
LEU
59
-176.55
126.80
2
A
LEU
68
69.11
64.25
2
A
ASN
72
65.96
63.69
2
A
GLU
73
179.39
43.32
2
A
GLN
74
-149.30
16.19
2
A
LEU
75
-154.50
21.27
3
A
ASP
12
179.00
48.71
3
A
SER
20
-105.89
-156.71
3
A
ASP
24
-157.07
-39.46
3
A
CYS
45
-100.01
73.92
3
A
ASN
48
178.56
-35.82
3
A
LEU
68
67.74
63.55
3
A
GLU
73
-179.76
34.51
3
A
GLN
74
-117.11
-74.51
3
A
GLU
76
-44.21
107.45
4
A
ASP
12
-173.81
35.62
4
A
ALA
16
40.89
83.97
4
A
ASN
48
178.81
-34.07
4
A
ASN
57
-121.82
-68.16
4
A
GLU
58
-58.95
90.20
4
A
LYS
65
-146.54
37.85
4
A
LEU
68
72.79
69.44
4
A
GLU
73
177.11
38.82
4
A
GLN
74
-146.25
17.56
4
A
LEU
75
-131.59
-47.63
4
A
GLU
76
-47.59
170.11
5
A
ASP
12
-169.84
33.81
5
A
CYS
19
-103.41
-60.02
5
A
SER
20
42.07
-164.98
5
A
SER
21
76.45
-3.14
5
A
ASP
22
162.65
37.52
5
A
ALA
31
-70.25
-166.44
5
A
LEU
33
-151.73
-59.43
5
A
PHE
47
-86.31
44.92
5
A
ASN
48
-157.80
-43.00
5
A
ASN
57
-170.97
49.29
5
A
GLU
58
-178.52
64.72
5
A
LYS
65
-142.91
28.90
5
A
GLU
73
-166.40
35.69
5
A
GLN
74
-121.81
-70.66
6
A
ASP
12
-172.93
40.28
6
A
LYS
14
-151.79
38.28
6
A
SER
20
-169.52
-153.62
6
A
ASP
22
77.76
43.20
6
A
ALA
31
-73.34
-163.26
6
A
CYS
45
-102.78
79.12
6
A
PHE
47
-89.12
40.58
6
A
ASN
48
-164.16
-42.44
6
A
ASN
57
-161.42
-43.15
6
A
LEU
59
-177.03
-164.72
6
A
TYR
61
-169.57
94.21
6
A
ASP
67
-50.37
98.07
6
A
LEU
68
62.65
61.42
6
A
ASN
72
49.35
75.20
6
A
GLU
73
172.24
42.32
7
A
ASP
12
-170.02
41.09
7
A
LYS
14
-153.17
40.71
7
A
ALA
16
46.22
84.76
7
A
CYS
19
-54.54
173.60
7
A
SER
20
-86.29
-157.27
7
A
ASP
24
-147.98
11.51
7
A
ALA
31
-54.47
-168.79
7
A
LEU
33
-163.55
39.96
7
A
CYS
45
-102.64
76.03
7
A
PHE
47
-92.74
48.23
7
A
ASN
48
-174.34
-39.33
7
A
GLU
56
-127.07
-161.95
7
A
ASN
57
-152.98
-58.62
7
A
ASP
67
-44.71
102.30
7
A
LEU
68
67.48
65.48
7
A
ASN
70
-101.10
70.56
7
A
GLU
73
-177.66
62.99
7
A
GLN
74
-158.81
-50.03
8
A
ASP
12
-159.54
37.04
8
A
LYS
14
-179.71
31.98
8
A
ALA
16
41.83
95.97
8
A
SER
21
165.78
-48.92
8
A
ASP
22
-145.83
36.22
8
A
ASP
24
-155.04
21.87
8
A
ALA
25
179.75
114.43
8
A
LYS
30
-151.28
89.54
8
A
PHE
47
-86.25
48.64
8
A
ASN
48
-164.86
-37.08
8
A
GLU
56
-117.68
-157.80
8
A
ASN
57
-157.69
-61.77
8
A
LEU
59
177.35
134.39
8
A
LYS
65
-142.27
31.33
8
A
ASP
67
-49.01
103.17
8
A
LEU
68
63.27
63.11
8
A
PHE
71
-178.68
31.85
8
A
GLU
73
-157.22
37.13
8
A
GLN
74
-125.80
-55.57
8
A
GLU
76
-48.01
162.31
9
A
ALA
11
-98.54
35.48
9
A
ASP
12
-178.69
43.59
9
A
CYS
13
-47.44
175.94
9
A
LYS
14
-179.92
32.23
9
A
ALA
16
46.75
97.59
9
A
SER
21
-173.79
54.39
9
A
ALA
25
-163.65
115.38
9
A
ALA
31
-57.01
173.76
9
A
LEU
33
-173.43
-43.82
9
A
ASN
48
-131.38
-34.59
9
A
VAL
50
-122.81
-54.78
9
A
GLU
56
-120.03
-167.46
9
A
ASN
57
-163.95
-40.81
9
A
LYS
65
-164.95
42.27
9
A
ASN
72
43.92
74.57
9
A
GLU
73
173.11
35.90
9
A
GLN
74
-109.85
-76.56
9
A
GLU
76
64.90
96.61
10
A
CYS
6
175.23
105.66
10
A
ASP
12
-157.09
33.78
10
A
LYS
14
-146.21
42.58
10
A
THR
15
-115.09
70.10
10
A
ASP
22
170.27
35.32
10
A
PHE
23
179.28
177.20
10
A
ASP
24
-170.42
26.37
10
A
ALA
25
164.21
124.26
10
A
ARG
55
71.36
34.88
10
A
ASN
57
-140.19
-71.67
10
A
LEU
59
-173.00
101.82
10
A
LYS
65
-168.49
28.64
10
A
LYS
66
-98.70
30.91
10
A
ASP
67
65.46
105.44
10
A
PHE
71
-107.97
-168.31
10
A
ASN
72
-94.49
55.78
10
A
GLU
73
-168.36
37.16
model building
X-PLOR
refinement
X-PLOR
phasing
X-PLOR
CD59 COMPLEXED WITH GLCNAC-BETA-1,4-GLCNAC-BETA-1 (NMR, 10 STRUCTURES)
STRUCTURE OF A SOLUBLE, GLYCOSYLATED FORM OF THE HUMAN COMPLEMENT REGULATORY PROTEIN CD59
1
Y
N
2
N
N
A
PHE
47
A
PHE
47
HELX_P
IRREGULAR H-BONDS AT C-T END
A
GLU
56
A
GLU
56
1
H1
10
disulf
2.019
A
CYS
3
A
SG
CYS
3
1_555
A
CYS
26
A
SG
CYS
26
1_555
disulf
2.021
A
CYS
6
A
SG
CYS
6
1_555
A
CYS
13
A
SG
CYS
13
1_555
disulf
2.019
A
CYS
19
A
SG
CYS
19
1_555
A
CYS
39
A
SG
CYS
39
1_555
disulf
2.020
A
CYS
45
A
SG
CYS
45
1_555
A
CYS
63
A
SG
CYS
63
1_555
disulf
2.021
A
CYS
64
A
SG
CYS
64
1_555
A
CYS
69
A
SG
CYS
69
1_555
covale
1.451
one
N-Glycosylation
A
ASN
18
A
ND2
ASN
18
1_555
B
NAG
1
B
C1
NAG
1_555
covale
1.391
both
B
NAG
1
B
O4
NAG
1_555
B
NAG
2
B
C1
NAG
1_555
covale
1.399
both
B
NAG
1
B
O6
NAG
1_555
B
FUC
3
B
C1
FUC
1_555
COMPLEMENT REGULATORY PROTEIN
COMPLEMENT REGULATORY PROTEIN
CD59_HUMAN
UNP
1
1
P13987
MGIQGGSVLFGLLLVLAVFCHSGHSLQCYNCPNPTADCKTAVNCSSDFDACLITKAGLQVYNKCWKFEHCNFNDVTTRLR
ENELTYYCCKKDLCNFNEQLENGGTSLSEKTVLLLVTPFLAAAWSLHP
26
102
1CDR
1
77
P13987
A
1
1
77
2
3
anti-parallel
anti-parallel
anti-parallel
A
LEU
1
A
LEU
1
A
CYS
6
A
CYS
6
A
THR
15
A
THR
15
A
CYS
19
A
CYS
19
A
GLN
34
A
GLN
34
A
TRP
40
A
TRP
40
A
ALA
25
A
ALA
25
A
ALA
31
A
ALA
31
A
LEU
59
A
LEU
59
A
LYS
65
A
LYS
65
1
P 1